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Abstract
Background: Activin A and its binding protein follistatin (FS) are increased in inflammatory disorders and sepsis.
Overexpression of activin A in the lung causes similar histopathological changes as acute respiratory distress
syndrome (ARDS). ARDS and severe respiratory failure are complications of influenza A(H1N1) infection. Interleukin 6
(IL-6), which in experimental studies increases after activin A release, is known to be related to the severity of H1N1
infection. Our aim was to evaluate the levels of activin A, activin B, FS, IL-6 and IL-10 and their association with the
severity of respiratory failure in critically ill H1N1 patients.
Methods: A substudy of a prospective, observational cohort of H1N1 patients in Finnish intensive care units (ICU).
Clinical information was recorded during ICU treatment, and serum activin A, activin B, FS, IL-6 and IL-10 were
measured at admission to ICU and on days 2 and 7.
Results: Blood samples from 29 patients were analysed. At the time of admission to intensive care unit, elevated
serum levels above the normal range for respective age group and sex were observed in 44% for activin A, 57% for
activin B, and 39% for FS. In 13 of the 29 patients, serial samples at all time points were available and in these the
highest activin A, activin B and FS were above the normal range in 85%, 100% and 46% of the patients, respectively.
No difference in baseline or highest activin A or activin B was found in patients with or without acute lung injury
(ALI) or ARDS (P > 0.05 for all). Peak levels of IL-6 were significantly elevated in ALI/ARDS patients. Peak activin A
and activin A/FS were associated with ventilatory support free-days, severity of acute illness and length of ICU stay
(P < 0.05 for all).
Conclusions: Higher than normal values of these proteins were common in patients with H1N1 infection but we
found no association with the severity of their respiratory failure.
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Background
Activins are dimeric proteins belonging to the trans-
forming growth factor beta (TGF-β) superfamily. Activin
A is involved in many physiological functions including
inflammation, tissue remodelling and repair [1-3]. In
acute inflammation caused by a lipopolysaccharide (LPS)
challenge, serum activin A levels are increased before
tumor necrosis factor α (TNFα), interleukin 1β (IL1β)
and interleukin 6 (IL6), and stimulate the activin-
binding protein, follistatin (FS) which peaks at 3-6 hours
post -LPS [4]. Activin has proinflammatory and anti-
inflammatory actions [5], and it may modulate the adap-
tive immune response [6]. Serum activin A is increased in
sepsis [7], which is the most common risk factor for acute
respiratory distress syndrome (ARDS) [8]. In ARDS pa-
tients, activin A levels in bronchoalveolar fluid (BAL) are
high, and in mice overexpression of activin A in lungs
leads to histopathology resembling human ARDS [9].
Follistatin regulates the activity of activins. Two forms
of FS, FS288 and FS315, are products of alternative
mRNA splicing. Blocking the action of activin A by FS
can halve the mortality of a lethal dose of LPS and high-
lights the role of activin A in inflammation, leading
to therapeutic interest (1). Bleomycin-induced rat lung
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fibrosis was attenuated [10], and adverse effects of acti-
vin A overexpression were decreased by the use of FS in
mice [9]. In vivo, blocking activin A enhances adaptive
immunity [6].
Influenza A(H1N1) caused a pandemic in year 2009.
The majority of H1N1 patients had a mild clinical course,
but a minority needed intensive care unit (ICU) treatment
for rapidly progressive severe respiratory failure of viral
pneumonitis and ARDS [11,12]. Early treatment with anti-
viral drugs may improve outcome of severe influenza [13],
but no specific treatment for ARDS is available. Severe
H1N1 infection is associated with hypercytokinemia
[14,15] and a dysregulated immune response [16]. The in-
crease in IL-6 has been found to correlate with respiratory
involvement in adult [17] and paediatric [18] patients. Fur-
ther, in ARDS caused by other aetiologies, high IL-6 levels
have been associated with worse outcomes [19]. Given
these results, any potential therapeutic approach that
ameliorates this inflammatory response and disease pro-
gression requires evaluation.
Accordingly, our study was carried out to assess the
pattern of the novel inflammatory regulators, activins
and FS, and to compare them with the classic inflam-
matory mediators IL-6 and IL-10 in critically ill H1N1
patients. Additionally, we evaluated the association of
these markers with the severity of acute illness and re-
spiratory failure in these patients.
Methods
Patients and study design
This study was a sub-study of the previously published
prospective observational cohort study of consecutive,
critically ill influenza A(H1N1) patients during the Finnish
H1N1 outbreak from 11 October 2009 to 31 December
2009 [20]. All study patients were confirmed H1N1 posi-
tive by real-time reverse polymerase chain reaction (PCR)
test. The main study consisted of 132 patients from 23 in-
tensive care units. This sub-study was conducted in four
ICUs and all 57 patients of these ICUs were considered
eligible for the study.
The ethics committee of Helsinki University Central
Hospital approved the study. In the main study informed
consent was waived for data collection from patient
charts. For this laboratory sub-study signed informed
consent was required from the patient or next-of-kin
prior to blood sample collection.
We recorded patient demographics and clinical data
with an internet-based clinical report form provided by
the Finnish Intensive Care Quality Consortium (Intensium
Ltd, Kuopio, Finland). The collected data has been
described in more detail previously [20]. Briefly, co-
morbidities, symptom and medication starting times, ven-
tilatory and other therapies, presence of severe sepsis or
septic shock and ARDS [21] were recorded. The degree of
hypoxemia was evaluated by partial pressure of arterial
oxygen divided by the fraction of inspired oxygen (PaO2/
FiO2).
Age, gender, Simplified Acute Physiology Score (SAPS)
II, Sequential Organ Failure Assessment (SOFA) score
components, hospital and ICU admission/discharge times,
and ICU and hospital mortality were acquired from the
routinely collected benchmarking data (Intensium Ltd,
Kuopio, Finland).
The blood samples were collected as soon as possible
after ICU admission (baseline), and on days 2 and 7.
The serum samples were stored at −20°C during the
study period, and then transferred and stored at −70°C
until analyzed. Serum activin A, activin B, and total FS
were determined using specific ELISAs for activin A and
B and by radioimmunoassay for follistatin [22-24]. The
intra-assay CV for activin A, activin B and FS were 5.7%,
2.7-6.2%, and 5.8%, respectively. The lower levels of
detections were as follows: activin A 7.7 pg/mL, activin
B 19.0 pg/mL and FS 1.44 ng/mL. Details of the pub-
lished defined age-related reference values of 138 healthy
persons were used for comparison (de Kretser et al.
2013) (Additional file 1). We calculated activin A:FS-
ratio (activin A/FS) as an indicator of available activin A
activity.
IL-6 levels in serum were measured by a specific
human IL-6 ELISA kit BD Biosciences, San Diego, CA
using a human recombinant IL-6 preparation supplied
with the kit. IL-10 serum levels were also measured
using a specific IL-10 ELISA kit, BD Biosciences, San
Diego using a human recombinant IL-10 provided with
the kit.
Statistical analysis
Data are presented as median with interquartile range
(IQR) or absolute values and percentages as appropriate.
We compared the non-parametric data of independent
groups using two-tailed Mann–Whitney test and those
of several groups using Kruskal-Wallis test. Repeated
measurements were compared with Friedman’s test.
Due to non-normality of activin A, activin B, and FS,
Spearman’s correlation coefficient (r) was used to test re-
lationships. We used SPSS 19 (IBM SPSS Inc, Chicago,
IL, USA and GraphPad 6 (GraphPad Software, LaJolla,
CA, USA) for statistical analysis.
Results
Consent for blood sampling was available from 29 out of
57 eligible patients. Demographic data of the study pa-
tients compared to H1N1 patients with no consent are
presented in Table 1. Median [IQR] of lowest PaO2/FiO2
was 100 [76–134] mmHg. Positive end-expiratory pre-
ssure (PEEP) at admission was 5 [4-8] cmH2O in non-
invasively ventilated (NIV) patients compared to 8.5
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[6.3-12.0] cmH2O in invasive ventilation, P < 0.05. No pa-
tient in the study was pregnant or in the postpartum state.
Oseltamivir and antibiotics treatment and time was re-
corded in 28 and in 26 of 29 patients, respectively. Cor-
ticosteroid medication was given to 19 patients; 9 patients
were treated for ARDS with or without shock or airway
obstruction and 7 patients for obstruction. Methylprednis-
olone was given to 17 patients, hydrocortisone to one and
3 patients received both. The median [IQR] duration of
corticosteroid therapy during ICU treatment was 3 [0.8]
days.
At baseline the medians [IQR] of serum activin A, acti-
vin B and FS were 0.098 [0.069-0.128] ng/mL, 0.084
[0.049-0.143] ng/mL, and 10.80 [8.60-19.12] ng/mL,
respectively. Activin A/FS at baseline was 0.0075 [0.0051-
0.0118]. At baseline the median [IQR] of IL-6 and IL-10
were 63.93 [42.80-189.91] pg/mL and IL-10 28.60 [16.28-
48.26] pg/mL, respectively. Data from other time points
are presented in Figure 1.
Of all study patients, serum activin A levels exceeded
the upper level of the normal range in 44% of patients at
admission (day 1), in 57% on day 2 and 69% on day 7.
For serum activin B levels those exceeding the upper
limit were 57% on day 1, 76% on day 2 and 54% on day
7. For serum follistatin, those patients exceeding the
upper limit of normal were 39% at day 1, 36% on day 2
and 15% at day 7.
Median [IQR] of highest values was 0.110 [0.085-
0.168] ng/mL for activin A, 0.122 [0.078-0.155] for acti-
vin B, 12.21 [8.90-19.57] for FS. As normal ranges for
the IL-6 and IL-10 assays were not available, the data for
these cytokines are provided as the IQR for day 1, day 2
and day 7 and for IL-6 on day 1, day 2 and day 7. The
IQR for the highest levels of IL6 was 122.91 [54.60-
Table 1 Characteristics of study patients compared to other patients
Included H1N1 patients n = 29 Other H1N1 patients ICUs n = 28 P value
Age, years 47 [39–56] 49 [37–55] 0.994
Gender, male 20 (69%) 17 (61%) 0.514
Obstructive pulmonary disease 9 (31%) 8 (29%) 0.839
Chronic cardiac insufficiency 9 (31%) 4 (14%) 0.207
Ischemic cardiac disease 9 (31%) 0 1.000
Body mass index >35 kg/m2 11 (39%) 4 (15%) 0.070
SAPS II, points 24 [20-32] 29 [24–39] 0.016
SOFA at 24 h, score 3 [2-7] 6 [3–8] 0.042
SOFA maximum, score 7 [3–9] 6 [4–11] 0.493
Time from symptoms to hospital admission, hours 132 [54–188] 72 [36–168] 0.115
Time from hospital admission to ICU admission 19 [12–33] 19 [8–35] 0.792
CRP (mg/L) at ICU admission 73 [33–163] 57 [26–199] 0.965
PaO2/FiO2 (mmHg) at ICU admission 135 [101–261] 132 [110–299] 0.492
PaO2/FiO2 (mmHg), lowest 100 [76–134] 111 [79–269] 0.274
Number of infiltrated quadrants on X-ray at admission 4 [2–4] 2 [1–3] 0.025
ALI or ARDS 19 (66%) 16 (57%) 0.516
Corticosteroid treatment 19 (66%) 13 (46%) 0.2923
Ventilatory support 0.144
No 3 (10%) 6 (21%)
Non-invasive 13 (45%) 6 (21%)
Invasive 13 (45%) 16 (57%)
CPAP or PEEP (mmHg) at admission 7 [5–12] 7 [6–8] 0.485
Length of ventilatory support, days 4 [2–10] 4 [0–9] 0.485
ICU length of stay, days 5 [2–10] 3 [1–9] 0.389
Hospital length of stay, days 12 [7–16] 11 [5–25] 0.812
ICU mortality 1 (83%) 0 1.000
Hospital mortality 1 (3%) 2 (7%) 0.611
SAPS, simplified acute physiology score; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit; ALI, acute lung injury; ARDS, acute respiratory
distress syndrome; CPAP, continuous positive airway pressure; PEEP, positive end-expiratory pressure, median [interquartile range].
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294.55] pg/mL and for IL-10 28.94 [17.78-49.31] pg/mL.
On day two IL-6 correlated with activin A (r = 0.664;
P = 0.001) and activin B (r = 0.438; P = 0.028) and activin
A/FS (r = 0.477; P = 0.016). Day two IL-10 correlated
with the respective activin B levels (r = 0.405, P = 0.045).
Highest IL-6 correlated with highest activin A (r = 0.599;
P = 0.001) and activin A/FS and (r = 0.590; P = .001).
Serial measurement data of patients with samples at
all time points (n = 13) are presented in Figure 2. The
highest activin B level exceeded normal range in all pa-
tients. Peak activin A and FS levels were above the nor-
mal range in 85% and 46% of patients, respectively.
Baseline activin B, activin A/FS and IL-6 were not asso-
ciated with oxygenation failure estimated by PaO2/FiO2 at
ICU admission or by lowest PaO2/FiO2 during ICU stay
(Table 2). At baseline, only higher IL-10 was associated
with admission oxygenation failure and higher admission
positive end-expiratory pressure (PEEP) (P < 0.05 for
both), but not with ventilator free days. Lower IL-6 was
associated with more ventilator free days, lower organ
failure score on the first day and a shorter length of stay
(LOS) in ICU (P < 0.05 for all).
The highest activin A and activin A/FS were associated
with less ventilator free days, higher acute disease severity
and longer length of stay in ICU, but not with admission
PEEP (Table 2). Peak IL-6 and IL-10 were associated with
higher admission levels of PEEP (P < 0.05), less ventilator
free days, higher acute disease severity and longer stays in
ICU.
No difference in the baseline or peak activin A and
activin B levels regarding ALI/ARDS or type of ventila-
tory support were found (Figure 3). At ICU admission,
IL-6 and IL-10 were higher in patients with ALI/ARDS
(P < 0.01 for both), and IL-10 was higher in patients
needing invasive ventilation (P < 0.05) on ICU admission.
The peak IL-6 level was higher in ALI/ARDS, and IL-6
and IL-10 were higher in invasively ventilated patients
(Figure 3).
Figure 1 Serum levels of activin A, activin B, follistatin, the activin A/follistatin ratio, interleukin 6 and interleukin 10 at baseline (D0),
and on days two (D2) and seven (D7). Highest values are also displayed. Markers represent individual patient values, and median with
interquartile range.
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Discussion
This study is the first report of elevated serum levels of
activin A, activin B and FS in critically ill patients with
H1N1 infection. In serial measurements activin A, acti-
vin A/FS increased, FS and IL-10 decreased, and IL-6
remained at the admission level during the first week of
ICU treatment.
Increase of activin A and FS is in accordance with previ-
ous findings in an LPS induced experimental sepsis model
[1] and in septic patients [7]. In septic patients, as in the
patients in our study, the levels of serum activin A tended
to be elevated for days. This finding differed from the
rapid peak (1 hour) and return to basal level (5 hours)
after experimental LPS injection [5]. In the LPS-induced
sepsis model, the higher serum level of activin A was asso-
ciated with a fatal outcome [1], but not in a small study of
septic patients [7]. The small sample size and low mortal-
ity in our study prevented any mortality analysis.
To our knowledge, activin B levels have not been re-
ported in critically ill patients. This study showed elevated
activin B levels in most of the patients, but the trend was
different compared to activin A, suggesting different regu-
latory mechanisms. In part this is reflected in the acute re-
sponse to LPS since the activin A response is rapid and
does not require new protein synthesis whereas the activin
B response is delayed and dependent on new protein syn-
thesis (Hedger et al. unpublished data). This novel finding
indicates the need for further studies to delineate the role
of activin B in inflammation and fibrosis. To date, activin
B, with an amino acid sequence homology to activin A of
65% has been considered as a less potent member of
this family of proteins as it was only partially able to
Figure 2 Activin A, activin B, follistatin, activin A/follistatin, interleukin 6 and interleukin 10 in subset of patients with all serial samples
(n = 13) at baseline (D0), and on days two (D2) and seven (D7). Data presented as median with interquartile range. Comparison made for
individual serial data.
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compensate for the absence of activin A in a mice with de-
letion of the activin A subunit [25].
In animal models, FS peaks (4 hours) after activin A
and stays elevated longer (24 hours). This pattern arises
from the capacity of activin A to stimulate FS produc-
tion [1]. As the trend of activin A was increasing during
the first 7 days, the trend of FS was decreasing. The in-
creasing activin A/FS, an indicator of available activin
activity, may implicate dysregulation of activin A and a
consequent lung injury. Strong expression of activin A
has been found on alveolar macrophages in diffuse al-
veolar damage, lung fibrosis, and in pulmonary arteries
Table 2 Association of baseline activin A, activin B and activin A/follistatin with severity of respiratory failure
Activin A Activin B Activin A/follistatin
PaO2/FiO2 at ICU admission D0 r = −0.093; P = 0.659 r = −0.073; P = 0.730 r = −0.023; P = 0.914
highest r = −0.181; P = 0.385 r = 0.124; P = 0.556 r = −0.132; P = 0.529
PaO2/FiO2 lowest during ICU stay D0 r = 0.122; P = 0.538 r = 0.186; P = 0.343 r = 0.105; P = 0.596
highest r = −1.31; P = 0.498 r = 0.052; P = 0.719 r = −0.117; P = 0.547
PEEP at admission D0 r = −0.071; P = 0.773 r = −0.093; P = 0.706 r = −0.039; P = 0.875
highest r = 0.297; P = 0.217 r = 0.118; P = 0.629 r = 0.102; P = 0.678
Ventilatory support free days D0 r = −0.143; P = 0.467 r = 0.100; P = 0.613 r = −0.068; P = 0.729
highest r = −0.452; P = 0.014 r = −0.166; P = 0.391 r = −0.446.; P = 0.015
SOFA score, at 24 hours D0 r = 0.351; P = 0.067 r = 0.047; P = 0.814 r = 0.222; P = 0.257
highest r = 0.466; P = 0.011 r = −0.095; P = 0.624 r = 0.369; P = 0.049
SAPSII score D0 r = 0.252; P = 0.196 r = −0.020; P = 0.921 r = 0.191; P = 0.330
highest r = 0.434; P = 0.019 r = −0.065; P = 0.739 r = 0.471; P = 0.010
C-reactive protein at ICU admission D0 r = 0.131; P = 0.516 r = 0.140; P = 0.485 r = 0.057; P = 0.778
highest r = 0.232; P = 0.235 r = 0.279; P = 0151 r = 0.201; P = 0.305
Length of ICU stay D0 r = 0.202; P = 0.303 r = −0.077; P = 0.698 r = 0.093; P = 0.638
highest r = 0.422; P = 0.023 r = −0.128; P = 0.507 r = 0.409; P = 0.028
ICU, intensive care unit; PEEP, positive end-expiratory pressure; SOFA, Sequential Organ Failure Assessment; SAPS, Simplified Acute Physiology Score; r, Spearman’s
correlation coefficient; D0, baseline.
Figure 3 Peak activin A, activin B, interleukin 6 and interleukin 10 according to ALI/ARDS (A) and type of ventilatory support (B).
Markers represent highest individual patient values, and median with interquartile range. Comparison made between all groups.
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in pulmonary hypertension [2], all of which findings may
be present in ARDS. Furthermore, the rapid increase in
lung activin concentrations in mice given LPS has been
shown to be due in part to the rapid movement of
neutrophils into the lungs and the presence of activin A
in their secretory granules [26]. Furthermore, TNFα
has the capacity to release activin A from neutrophil
secretory granules [27]. Recently, Apostolou and col-
leagues demonstrated that histopathology in ARDS was
associated with overexpression of activin A in mice
lungs and, additionally, activin A was elevated in BAL
fluid in ARDS patients [9].
Of note, contrary to expectations, we found no asso-
ciation between circulating activin A, FS or activin A/FS
and ALI/ARDS. There may be several explanations for
this result. First, the evidence of parallel circulating activin
A and expression in lungs and/or BAL fluid in patients
is still lacking. The degree of oxygenation failure in our
patients was severe and, thus, obtaining BAL samples,
unnecessary to patient treatment, was not justified. Sec-
ond, compared to animal studies, patient cohorts are
more heterogeneous. Although, in this study, all patients
were confirmed to have the same infection, other stan-
dardization was not possible and different co-morbid con-
ditions, obesity, and septic bacterial secondary infections
were present. Third, time from the start of symptoms to
hospitalisation and ICU treatment was relatively short,
and thus, prompt treatment with oseltamivir and antibi-
otics may have influenced disease severity and outcome.
In addition, the more severely ill patients were more likely
to have been treated with corticosteroids [28]. Corticoste-
roids suppress systemic inflammation in ARDS patients
[29], and together with a neuraminidase inhibitor may
attenuate tissue damage during experimental influenza
infection [30]. Further, administration of glucocorticoids
also suppresses activin A expression [31,32]. Mechanical
ventilation [33], prone position [34], and neuromuscular
blocking agents [35] all may affect the inflammatory re-
sponse. Finally, although we analyzed all available samples
from cohort of patients with H1N1, due to required in-
formed consent, the patients were not consecutive and the
sample size was relatively small. This may have caused a
type II error in detecting existing differences in activin
and FS levels with regard to disease severity.
In accordance with the previous studies in ARDS [19], we
found higher IL-6 in ALI/ARDS patients. Our results also
corroborate with previous studies showing an IL-6 increase
with respiratory severity in H1N1 influenza [14,15,17,18].
Interestingly, the evolution of IL-6, IL-10 and activin A
were different over time. Activin A, activin B and activin
A/FS correlated with IL-6 only on day two.
The importance of measuring activin A and B in criti-
cally ill patients was illustrated by our previous study of
patients in ICU with acute respiratory failure [36]. That
study established that patients with both serum activin
A and B above the normal range had the highest mor-
tality levels. This outcome may be associated with the
capacity of increased levels of activin A to cause apop-
tosis of hepatocytes and B lymphocytes and to cause the
production of nitric oxide (reviewed in [37]). Further ex-
ploration of the capacity of soluble activin receptor
blockers and follistatin as agents capable of regulating
the bioactivity of the activins and their possible role in
the treatment of such patients may be of value in the
future.
To our knowledge, this is the first study to report in-
creased levels of activin A, activin B and FS, compared
to normal range, and simultaneous IL-levels in severe
H1N1 influenza. Regrettably, the inclusion of only criti-
cally ill patients prevented evaluation of potential asso-
ciation between these inflammatory markers and disease
severity, which needs to be scrutinized in a larger popu-
lation of critically ill patients.
Conclusions
This study establishes that in critically ill patients with
severe H1N1 Influenza, the levels of activins A, B and
follistatin are elevated in a significant proportion of pa-
tients. However, the magnitude of the increase did not
correlate with the severity of the infection and the de-
gree of respiratory failure.
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- The baseline levels of Activin A and B did not correlate with the severity of
respiratory symptoms in critically ill influenza A(H1N1) patients, but highest
activin A and activin A/FS levels correlated with less ventilator free days,
increased acute disease severity and increased ICU LOS
- Future studies are justified to explore the role of acitivins and follistatin in
ARDS.
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